Article
Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: Analysis of over 8000 cases.
Cancer - 15 Jul 2020
Mack Philip C, Banks Kimberly C, Espenschied Carin R, Burich Rebekah A, Zill Oliver A, Lee Christine E, Riess Jonathan W, Mortimer Stefanie A, Talasaz AmirAli, Lanman Richard B, Gandara David R
Abstract excerpt
BACKGROUND: Circulating cell-free tumor DNA (ctDNA)-based mutation profiling, if sufficiently sensitive and comprehensive, can efficiently identify genomic targets in advanced lung adenocarcinoma. Therefore, the authors investigated the accuracy and clinical utility of a commercially available digital next-generation sequencing platform in a large series of patients with non-small cell lung cancer (NSCLC)....
Topics
- Adenocarcinoma of Lung
- Alleles
- Biomarkers, Tumor
- Carcinoma, Non-Small-Cell Lung
- Circulating Tumor DNA
- Cohort Studies
- Disease Progression
- Drug Resistance, Neoplasm
- ErbB Receptors